PURE Bioscience (OTCMKTS:PURE) Short Interest Up 100.2% in July

Posted by Dante Gardener on Aug 15th, 2026

PURE Bioscience (OTCMKTS:PURE – Get Free Report) was the recipient of a large increase in short interest in July. As of July 31st, there was short interest totaling 7,738 shares, an increase of 100.2% from the July 15th total of 3,865 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average daily volume of 32,276 shares, the days-to-cover ratio is currently 0.2 days.

PURE Bioscience Stock Performance

Shares of PURE Bioscience stock opened at $0.08 on Friday. PURE Bioscience has a 52 week low of $0.04 and a 52 week high of $0.14. The stock has a market cap of $10.40 million, a PE ratio of -2.67 and a beta of 0.21. The company’s 50-day moving average price is $0.07 and its two-hundred day moving average price is $0.07.

PURE Bioscience (OTCMKTS:PURE – Get Free Report) last announced its quarterly earnings data on Monday, June 15th. The company reported ($0.01) earnings per share (EPS) for the quarter. The firm had revenue of $0.51 million for the quarter.

About PURE Bioscience

(Get Free Report)

PURE Bioscience, Inc is a San Diego, California–based company that develops and markets patented antimicrobial solutions for diverse industries. At the core of its technology portfolio is Silver Dihydrogen Citrate (SDC), an EPA-registered broad-spectrum biocide designed to neutralize bacteria, viruses, and fungi on contact. The company targets applications in food processing, water treatment, personal care, and medical device sanitation.

PURE’s product suite includes concentrate formulations and ready-to-use solutions.